ServiceNow AI Partnership: -1.8% Shock Tests Bull Case
Can the new ServiceNow AI Partnership with DXC turn a sharp stock pullback into a long-term upside story for investors? Maik Kemper Editor in Chief Putting ServiceNow’s Core…
Advanced Micro Devices AI Strategy Boom Toward Tens of Billions
Can the Advanced Micro Devices AI Strategy really turn GPUs, CPUs and full racks into a tens-of-billions data center powerhouse? Maik Kemper Editor in Chief Conclusion In sum,…
Eli Lilly Weight Loss Drugs Boom: Can Foundayo Defend Margins?
Can Eli Lilly’s new Foundayo pill and GLP‑1 pipeline keep its obesity lead as a brutal price war erupts? Maik Kemper Editor in Chief Conclusion Overall, the expanding…
Cloudflare Agentic Web Partnership: Stock Soars +2.1% on AI Agent Push
Can Cloudflare’s new Agentic Web Partnership with GoDaddy turn AI agents into a profitable, permission-based growth engine for NET shareholders? Maik Kemper Editor in Chief We want to…
ServiceNow AI Partnership: -1.8% Shock or New Upside Opportunity?
Can the new ServiceNow AI Partnership with DXC turn today’s share price weakness into tomorrow’s proof point for long-term upside? Maik Kemper Editor in Chief Putting ServiceNow’s Core…
AMD AI Strategy Record: Can Data-Center Boom Last?
Can the AMD AI Strategy built around OpenAI, Meta and Helios really justify a premium valuation in the next AI cycle? Maik Kemper Editor in Chief Conclusion In…
Eli Lilly Weight-Loss Strategy vs Novo: Price War Shock
Can the Eli Lilly Weight-Loss Strategy stay on top as Novo Nordisk slashes prices and AI reshapes the obesity drug race? Maik Kemper Editor in Chief Conclusion In…
Amazon Logistics Deal Warning reshapes USPS and fees
Is the new Amazon Logistics Deal with USPS just routine housekeeping or a quiet reset of Amazon’s delivery, fee and AI ambitions? Maik Kemper Editor in Chief Conclusion…
Bitcoin Market Analysis Warning: Is a Short Squeeze Next?
Is macro panic hiding a Bitcoin bottom, or is the market sleepwalking into a brutal shakeout and potential short squeeze? Maik Kemper Editor in Chief Markets may still…
Novo Nordisk Wegovy Strategy Boom With HD Dose Push
Can Novo Nordisk’s aggressive Wegovy strategy really outflank Eli Lilly in the GLP-1 obesity war before new rivals scale up? Maik Kemper Editor in Chief The Wegovy HD…